SKYE Stock Analysis: Buy, Sell, or Hold?
SKYE - Skye Bioscience, Inc. Common Stock
$0.70
0.03 (3.75%)
▲
5d:
-1.12%
30d:
-1.86%
90d:
+5.35%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When SKYE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SKYE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SKYE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SKYE is currently trading at $0.70, which is considered slightly low relative to its 30-day fair value range of $0.69 to $0.79.
Technical Outlook: Technically, SKYE is showing sideways momentum. The price is currently testing key support at $0.68. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: SKYE has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.71 (+1001.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SKYE is showing sideways momentum. The price is currently testing key support at $0.68. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: SKYE has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.71 (+1001.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.69 -
$0.79
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 1001.3% below Wall St target ($7.71)
Trading Range Analysis
30-Day Trading Range
$0.69 -
$0.79
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$0.86
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.62
Wall Street Target
$7.71
(+1001.3%)
Share & Embed Analysis
Last updated: July 02, 2026 9:42 PM ET
Data refreshes hourly during market hours. Next update: 10:42 PM
Data refreshes hourly during market hours. Next update: 10:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SKYE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
